i2 cancers likely developed through initial expansion from an LGR5+ crypt bottom stem cell, acquiring copy number alterations and aneuploidy accelerated by TP53 mutations and characterized by prominent WNT pathway activation from an early loss-of-function APC mutation. The gene discussed is TP53; the disease is cancer.